US appeals court says class certification in Opana ER case requires more consideration
MLex Summary: Endo Pharmaceuticals has gotten antitrust claims over the drug Opana ER remanded by a US court of appeals for reconsideration of a class certification order. “As petitioners correctly point...To view the full article, register now.
Already a subscriber? Click here to view full article